Faculty

Pollack, Mark, MD

Director, Center for Anxiety and Traumatic Stress Disorders, MGH
Chief Medical Officer, Home Base Program, MGH
Professor of Psychiatry, Harvard Medical School

Biography

Dr. Mark Pollack is Director of the Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, and Professor of Psychiatry at Harvard Medical School. He received his medical degree in 1982 from New Jersey Medical School, and completed residency and fellowship training in psychiatry at Massachusetts General Hospital.

Dr. Pollack has received federal funding from the National Institute of Mental Health (NIMH) and National Institute of Drug Abuse (NIDA) to study the longitudinal course of panic disorder, the application of cognitive-behavioral intervention of benzodiazepine discontinuation in panic disorder patients to the reduction of illicit drug use in drug abusers, the impact of recent terrorist attacks on the development of PTSD and course of disorder in bipolar patients, changes in brain function as assessed by MR Spectroscopy and neuropsychological testing in patients on methadone maintenance, and treatment response and pharmacogenetics in refractory social anxiety disorder, and the use of d-cycloserine to enhance the treatment efficacy of cognitive-behavioral therapy in social anxiety disorder.

He has published over 300 articles, reviews and chapters, and is co-editor of the books Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies, Panic Disorder and its Treatment, and Social Phobia: Research and Practice. Dr. Pollack is editor-in-chief of the journal CNS Neuroscience and Therapeutics, lectures widely in national and international forums, serves on numerous editorial and advisory boards, as well as the Scientific Advisory Board of the Anxiety Disorders Association of America and the Board of Directors of the Mood and Anxiety Disorders Institute of the Massachusetts General Hospital.

His areas of clinical and research interest include the acute and long-term course, pathophysiology and treatment of patients with anxiety disorders and associated comorbidities, development of novel pharmacologic agents for mood and anxiety disorders, uses of combined cognitive-behavioral and pharmacologic therapies for treatment refractory patients, presentation and treatment of anxiety in the medical setting, and the pathophysiology and treatment of substance abuse.

Disclosure

Research Support

Pfizer, AstraZeneca, Sepracor, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Roche Laboratories, UCB Pharma, Wyeth, Cyberonics, NARSAD, NIDA, NIMH, Cephalon, and Forest.

Speaker/Honoraria

Pfizer, Solvay, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Wyeth, and Forest.

Advisory/Consulting

BrainCells Inc, Dov Pharma, Jazz Pharma, MedAvante, Neurocrine, Neurogen, Novartis, Otsuka Pharma, Pfizer, AstraZeneca, Sanofi, Sepracor, Solvay, Tikvah Therapeutics, Transcept Inc, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen, Eli Lilly & Co., Roche Laboratories, UCB Pharma, Wyeth, Cephalon, Forest, and Predix.

Shareholder

MedAvante and Mensante Corp.

Copyright Royalties:

SIGH-A and SAFER

Last updated: 7/27/2010

Courses

Privacy Statement

This website uses Echo360 technologies. Echo360 partners with the world’s leading educational institutions and industry associations to enhance the teaching and learning experience for students and professionals like you. Our goal is to enable a more engaging and successful learning experience by providing you with live and on-demand access to study tools, videos, and collaboration capabilities in an online classroom to help you achieve your educational goals. We believe you should always know what data we collect from you and how we use it. As part of our ongoing commitment to transparency, and to support new European data protection laws, we're updating our Privacy Policy to inform you about the information that you share with us.

The revised policy will take effect on May 25, 2018. By using our services on or after that date, you'll be agreeing to these updates. We encourage you to read this document in full.

Echo360, Inc. 11955 Freedom Drive, Suite 700, Reston, VA 20190 USA